alternatives to glp-1 agonists Comparing Ozempic, Wegovy and Other Drugs Ozempic Alternatives: GLP-1 Options &

Our exclusion criteria comprised non-original designs, studies investigated on internal GLP-1, studies lacking weight change outcomes, studies without all population undergoing bariatric surgery, absence of baseline patient characteristics

NEJM Evid

Best for: People who cannot use any GLP-1 class medication, or as an add-on to boost results

To successfully employ an all-comers strategy moving forward, manufacturers need to ensure products have strong clinical and/or non-clinical differentiation, a robust data package that addresses a range of patient types and comorbidities, and well-funded physician and patient facing marketing campaigns

Gastrointestinal adverse events affected 79.6% of the CagriSema group in REDEFINE 1, compared to 39.9% with placebo